Skip to main content

Table 2 Comparison of surgical resection versus transarterial chemoembolization with or without radiofrequency ablation of patients withBCLC stage B hepatocellular carcinoma after propensity score matching

From: Comparison of overall survival on surgical resection versus transarterial chemoembolization with or without radiofrequency ablation in intermediate stage hepatocellular carcinoma: a propensity score matching analysis

VariableSR (n = 140)TACE+RFA (n = 16)P-valueSR (n = 140)TACE (n = 87)P-value
Male117 (83.6)13 (81.3)0.220117 (83.6)67 (77.0)0.813
Age (years)62 (35–82)66 (35–87)0.24962 (35–82)64 (36–87)0.121
Smoking68 (48.6)8 (50.0)0.47268 (48.6)38 (43.7)0.914
Alcohol use58 (41.4)7 (43.8)0.85858 (41.4)35 (40.2)0.858
HBV positive70 (50.0)10 (62.5)0.20670 (50.0)36 (41.4)0.343
HCV positive30 (21.4)6 (16.7)0.06930 (21.4)26 (29.8)0.148
Total Bilirubin1.03 ± 0.431.21 ± 0.540.1861.03 ± 0.431.11 ± 0.500.061
INR1.00 ± 0.061.04 ± 0.100.0611.00 ± 0.061.03 ± 0.090.051
Cirrhosis36 (25.7)6 (37.5)0.09836 (25.7)31 (35.6)0.111
Child-Pugh class A134 (95.7)14 (87.5)0.236134 (95.7)80 (92.7)0.158
Tumor size8.2 ± 3.36.6 ± 2.80.9038.2 ± 3.38.2 ± 3.50.063
Tumor size≥5 cm127 (90.7)12 (75.0)0.186127 (90.7)75 (86.2)0.071
Tumor number (≥3)49 (35.0)9 (56.2)0.07549 (35.0)41 (47.1)0.058
AFP (ng/mL) ≥ 20034 (24.3)2 (12.5)0.40534 (24.3)17 (19.5)0.289
Mortality50 (35.7)11 (68.8)< 0.000150 (35.7)70 (80.5)0.010
Follow up times (months)39 (1–98)26 (9–76)< 0.000139 (1–98)21 (2–97)0.240
  1. BCLC stage Barcelona clinic liver cancer; SR Surgical resection; TACE Transcatheter arterial chemoembolization; RFA Radiofrequency ablation; HBV Hepatitis B virus; HCV Hepatitis C virus; AFP: INR International normalize ratio; Alpha-fetoprotein;